The Blue Box, a medtech startup based in Barcelona, has secured €3 million in seed funding to advance its innovative breast cancer screening technology. Utilizing artificial intelligence, the company has developed a urine-based test that analyzes volatile organic compounds to detect breast cancer biomarkers with 88% sensitivity. This approach addresses the limitations of traditional mammography, particularly for women with dense breast tissue. The funding round was led by Unconventional Ventures, with participation from several other investors, including the Spanish Association Against Cancer. The technology, originating from research at the University of Barcelona, aims to improve early detection rates and reduce false positives in national screening programs. The Blue Box plans to conduct clinical trials across seven European hospitals, with the goal of obtaining regulatory approval for its device as a primary screening method. Additionally, the company is exploring the potential to adapt its platform for detecting other types of cancer.
How is The Blue Box revolutionizing breast cancer screening with €3M funding?
